DEFINITION of 'Macaroni Defense'

The Macaroni Defense is one of many approaches a company may adopt to prevent an unwanted acquisition, or a hostile takeover. Takeovers are quite common, but in many cases, the target company is opposed to it because it believes the bid is too low or other reasons. There are many preemptive or reactive defensive strategies that management can use during merger and acquisition activity, and almost all of these strategies are aimed at affecting the value of the target's stock price, or corporate bonds in the Macaroni Defense.

In the Macaroni Defense, the target company issues a large number of bonds with the condition they must be redeemed at a high price if the company is taken over. The issuance has to be big enough to scare off the raider.

BREAKING DOWN 'Macaroni Defense'

Why is it called the Macaroni Defense? Because if a bidder tries to purchase the company, the redemption price of the bonds expands like macaroni in a pot. The downside of the strategy is that the company may saddle itself with too much debt and have difficulty making the interest payments, even if it successfully dissuades a takeover. Takeover-target companies can also use leveraged recapitalization to make themselves less attractive to the bidding firm.

Other methods to prevent a hostile takeover include golden parachute, green mail, people pill and poison pill.

Example of Blocking a Hostile Takeover

In July 2015, generic pharmaceutical company Mylan attempted to to block a hostile takeover bid by Israeli company Teva Pharmaceutical Industries by setting up an independent Dutch foundation, Stichting Preferred Shares Mylan. The foundation was able to issue or purchase preferred Mylan shares when it deemed its stakeholder interests were at risk. Stichting Preferred Shares planned to use its voting rights to oppose the Teva bid after exercising a call option to acquire preferred shares in Mylan and enabling it to own half the company. A few days later, Teva withdrew its bid for Mylan after it reached a deal with Allergan to acquire Allergan Generics.

RELATED TERMS
  1. Self-Tender Defense

    A self-tender defense is a defense against a hostile takeover, ...
  2. Poison Put

    A poison put is a takeover defense strategy in which the target ...
  3. Takeover

    A takeover occurs when an acquiring company makes a bid in an ...
  4. Pac-Man

    Pac-Man is a hostile takeover defense tactic in which a target ...
  5. "Just Say No" Defense

    A "just say no" defense is a strategy used by boards of directors ...
  6. Clandestine Takeover

    Clandestine takeover is an attempt to gain control over a company ...
Related Articles
  1. Investing

    The Pharmaceutical Feud: Mylan, Teva and Perrigo

    Find out what Tipranks' analysts think about several pharmaceutical giants competing in the realm of mergers and acquisitions.
  2. Investing

    Mylan's FDA Approval Isn't All That: Wells Fargo

    While Mylan's 17% rally this week is 'a little bit exaggerated,' a 'key win' could boost EPS.
  3. Investing

    Poison Pill

    A poison pill is a corporate maneuver put in place to try and prevent a hostile takeover. The target corporation uses this strategy to make its stock less attractive to the acquirer. This is ...
  4. Investing

    Teva Pharma to Acquire Allergan: Analysts Weigh In

    Teva Pharmaceutical announced a definitive agreement to buy Allergan Inc. for $40.5 billion. What analysts are saying?
  5. Investing

    Mylan's Price Hike: EpiPen Suit May Go Nationwide

    A woman whos EpiPen bill rose twelvefold in a year filed a class action suit against Mylan last month. If the class is certified, any EpiPen user can join.
  6. Investing

    Trademarks of a Takeover Target

    These tips on finding viable takeover targets can lead you to little companies with big prospects.
  7. Investing

    Teva Will Sink 50% After Fitch Downgrade: HSBC

    Numerous factors will continue to weigh on shares of the Israeli pharmaceutical giant, says HSBC.
  8. Investing

    TEVA's Ever-Narrowing Margin for Error

    Teva barely topped analyst expectations in its fiscal first quarter, but it has little margin for error.
  9. Investing

    FDA Rejects Mylan's Generic Version of Advair

    Glaxo is relieved after the FDA rejected rival Mylan's generic version of GSK's Advair.
  10. Trading

    Is Teva Pharmaceutical Stock Finally Bottoming Out?

    Teva has seen its shares slide since second quarter results, which could set the stage for a relief rally.
RELATED FAQS
  1. How can a company resist a hostile takeover?

    Learn about some of the defensive strategies a public company's board of directors might utilize to prevent a hostile bidder ... Read Answer >>
  2. What's the difference between a merger and a hostile takeover?

    Understand the difference between a merger and a hostile takeover, including the different ways one company can acquire another, ... Read Answer >>
  3. What are some of the top hostile takeovers of all-time?

    Learn about some of the most noteworthy hostile takeovers in history, including the KKR acquisition of RJR Nabisco and the ... Read Answer >>
  4. What is the difference between a merger and a takeover?

    In a general sense, mergers and takeovers (or acquisitions) are very similar corporate actions - they combine two previously ... Read Answer >>
  5. What is the significance of a Schedule 13D?

    A Schedule 13D is significant because it provides investors with useful information on everything an investor could want ... Read Answer >>
Trading Center